Faculty

David Shoultz

Affiliate Associate Professor, Epidemiology
Affiliate Associate Professor, Global Health

206-285-3500
darthur@uw.edu

Education

MBA Seattle University, 2012
PhD Epidemiology, University of Washington, 1997
MS Epidemiology, University of Washington, 1995
BSN University of Washington, 1991

Contact

206-285-3500
darthur@uw.edu

PATH
Seattle, WA

Bio

Dr. David Shoultz is the Global Program Leader for Drug Development at PATH. PATH is an international organization that drives transformative innovation to save lives and improve health, especially among women and children. PATH works across five platforms – vaccines, drugs, diagnostics, devices, and system & service innovations. PATH works with countries and other partners around the world to bring innovation to scale. PATH’s Drug Development program is working to discover, develop, and deliver safe, effective, and affordable new treatments for diseases disproportionately affecting people in developing countries.

Prior to joining PATH in November 2014, David was the director of grantee & partner engagement at the Bill & Melinda Gates Foundation and a member of the foundation’s leadership team. Having joined the Gates Foundation in 2009, David held several different roles at the foundation, including deputy director in the Global Health Program. He was also the relationship manager for PATH, and served as board member at OneWorld Health, the predecessor to the PATH Drug Development program.

Dr. Shoultz received his bachelor’s degree, MS, and Ph.D from the University of Washington in Seattle. His MBA is from the Albers School of Business & Economics at Seattle University, where he is a faculty member in the Executive MBA Program. For the past 14 years, he has been a member of the affiliate faculty for the departments of Global Health and Epidemiology at the University of Washington.

Prior to joining the foundation, Dr. Shoultz worked as a member of the senior management team for a number of clinical research organizations, participating in the development of new medicines, including PPD, PRA International, and Biomedical Systems.

In addition to his role at the Gates Foundation, Dr. Shoultz is on the Board of the Geneva Foundation, where he also served as the inaugural chair of the Scientific Advisory Committee until 2017.

Research Interests

I am interested in global health product discovery, development, and delivery. I am also interested in innovative finance for global health product development. I am eager to collaborate with other faculty members and am available to work with master’s and doctoral students who share my interests and commitment to global health product development.

Recent Publications (PubMed)

Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016.
(2018 Nov)
Lancet Infect Dis 18(11): 1229-1240
Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, Brewer TG, Engmann CM, Houpt ER, Kang G, Kotloff KL, Levine MM, Luby SP, MacLennan CA, Pan WK, Pavlinac PB, Platts-Mills JA, Qadri F, Riddle MS, Ryan ET, Shoultz DA, Steele AD, Walson JL, Sanders JW, Mokdad AH, Murray CJL, Hay SI, Reiner RC Jr

Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study.
(2018 Jul)
Lancet Glob Health 6(7): e758-e768
Khalil IA, Troeger C, Rao PC, Blacker BF, Brown A, Brewer TG, Colombara DV, De Hostos EL, Engmann C, Guerrant RL, Haque R, Houpt ER, Kang G, Korpe PS, Kotloff KL, Lima AAM, Petri WA Jr, Platts-Mills JA, Shoultz DA, Forouzanfar MH, Hay SI, Reiner RC Jr, Mokdad AH

Addressing Cryptosporidium Infection among Young Children in Low-Income Settings: The Crucial Role of New and Existing Drugs for Reducing Morbidity and Mortality.
(2016 Jan)
PLoS Negl Trop Dis 10(1): e0004242
Shoultz DA, de Hostos EL, Choy RK

Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy.
(2003 Jun 15)
Am J Med 114(9): 723-8
Tice AD, Hoaglund PA, Shoultz DA

Risk factors and treatment outcomes in osteomyelitis.
(2003 May)
J Antimicrob Chemother 51(5): 1261-8
Tice AD, Hoaglund PA, Shoultz DA

Show complete publication list